GBIO Quote, Financials, Valuation and Earnings

Moderna, Inc. has a net margin of -346.3% compared to Generation Bio Co.'s net margin of -121.83%. Generation Bio Co.'s return on equity of -84.94% beat Moderna, Inc.'s return on equity of -29.19%.

Generation Bio Co. has a consensus price target of $5.00, signalling downside risk potential of -6.37%. On the other hand Moderna, Inc. has an analysts' consensus of $41.75 which suggests that it could fall by -16.28%. Given that Moderna, Inc. has more downside risk than Generation Bio Co., analysts believe Generation Bio Co. is more attractive than Moderna, Inc..

Generation Bio Co. has a beta of 2.046, which suggesting that the stock is 104.637% more volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.318, suggesting its more volatile than the S&P 500 by 31.821%.

Generation Bio Co. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Generation Bio Co. pays -- of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend.

Generation Bio Co. quarterly revenues are $1.6M, which are smaller than Moderna, Inc. quarterly revenues of $678M. Generation Bio Co.'s net income of -$5.5M is higher than Moderna, Inc.'s net income of -$826M. Notably, Generation Bio Co.'s price-to-earnings ratio is -- while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Generation Bio Co. is 7.62x versus 9.98x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals, Inc. has a net margin of -346.3% compared to Generation Bio Co.'s net margin of 36.91%. Generation Bio Co.'s return on equity of -84.94% beat Vertex Pharmaceuticals, Inc.'s return on equity of 22.97%.

Generation Bio Co. has a consensus price target of $5.00, signalling downside risk potential of -6.37%. On the other hand Vertex Pharmaceuticals, Inc. has an analysts' consensus of $530.70 which suggests that it could grow by 11.28%. Given that Vertex Pharmaceuticals, Inc. has higher upside potential than Generation Bio Co., analysts believe Vertex Pharmaceuticals, Inc. is more attractive than Generation Bio Co..

Generation Bio Co. has a beta of 2.046, which suggesting that the stock is 104.637% more volatile than S&P 500. In comparison Vertex Pharmaceuticals, Inc. has a beta of 0.303, suggesting its less volatile than the S&P 500 by 69.725%.

Generation Bio Co. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Generation Bio Co. pays -- of its earnings as a dividend. Vertex Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Generation Bio Co. quarterly revenues are $1.6M, which are smaller than Vertex Pharmaceuticals, Inc. quarterly revenues of $3.2B. Generation Bio Co.'s net income of -$5.5M is lower than Vertex Pharmaceuticals, Inc.'s net income of $1.2B. Notably, Generation Bio Co.'s price-to-earnings ratio is -- while Vertex Pharmaceuticals, Inc.'s PE ratio is 31.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Generation Bio Co. is 7.62x versus 10.19x for Vertex Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

XOMA Royalty Corp. has a net margin of -346.3% compared to Generation Bio Co.'s net margin of 52.48%. Generation Bio Co.'s return on equity of -84.94% beat XOMA Royalty Corp.'s return on equity of 17.31%.

Generation Bio Co. has a consensus price target of $5.00, signalling downside risk potential of -6.37%. On the other hand XOMA Royalty Corp. has an analysts' consensus of $64.50 which suggests that it could grow by 149.9%. Given that XOMA Royalty Corp. has higher upside potential than Generation Bio Co., analysts believe XOMA Royalty Corp. is more attractive than Generation Bio Co..

Generation Bio Co. has a beta of 2.046, which suggesting that the stock is 104.637% more volatile than S&P 500. In comparison XOMA Royalty Corp. has a beta of 0.855, suggesting its less volatile than the S&P 500 by 14.461%.

Generation Bio Co. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XOMA Royalty Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.54 per share. Generation Bio Co. pays -- of its earnings as a dividend. XOMA Royalty Corp. pays out 39.59% of its earnings as a dividend. XOMA Royalty Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Generation Bio Co. quarterly revenues are $1.6M, which are smaller than XOMA Royalty Corp. quarterly revenues of $9.4M. Generation Bio Co.'s net income of -$5.5M is lower than XOMA Royalty Corp.'s net income of $10.3M. Notably, Generation Bio Co.'s price-to-earnings ratio is -- while XOMA Royalty Corp.'s PE ratio is 34.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Generation Bio Co. is 7.62x versus 8.98x for XOMA Royalty Corp.. Usually stocks with elevated PS ratios are considered overvalued.